Compare Ascendis Pharma A/S (ASND) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Entegris Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Entegris Inc trades at $141.29 (market cap $22.14B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.28% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ENTG | |
|---|---|---|
Market Cap | $17.74B | $22.14B |
Sector | Health | Technology |
52-Week High | $277.18 | $184.00 |
52-Week Low | $163.32 | $68.80 |
Enterprise Value | $18.11B | $25.45B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ENTG trades at $145.35, down 0.51% today, with technical indicators showing a bearish trend and support at $143. The company reported Q1 2026 EPS of $0.86, beating estimates, but maintains premium valuations with a P/E of 84.02. Revenue has been stable around $3.2B annually, with net income margins improving to 8.18% in 2026. Analyst sentiment remains positive with a $178.40 price target, though recent news highlights volatility and valuation concerns.
Outlook: ENTG benefits from semiconductor industry tailwinds and AI-driven demand, but faces risks from high valuation and market volatility. The stock offers potential upside based on analyst targets, but investors should monitor earnings consistency and competitive pressures in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
